Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...

Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...

MicroTransponder Clinical Trial Results Published in Stroke After Company Completes a $5.5M Round of Funding DALLAS, TX--(Marketwired - December 10, 2015) - MicroTransponder, Inc., (www.microtransponder.com) a privately-held medical device company, is pleased to announce that its successful stroke...